Plenary sessions speakers at BioFIT, Picture: © Vincent ESCHMANN

BioFIT is Europe’s leading partnering event in Life Sciences for tech transfer, early-stage innovation deals and pre-seed, seed and Series A investment, receiving each year more than 1,000 delegates from over 35 countries. For its 11th edition, BioFIT will be held in Strasbourg, France on November 29th and 30th, and on a digital format on December 7th and 8th.

© gerald/pixabay.com

Jolt Capital contributed $20m to the BC Platforms’ data footprint expansion on November 8th.

Ganoderma lucidum growing under oak in California. © Shane Hanofee

Researchers from the University of Linz (Austria) report progress on the way to make electronic devices more sustainable and more recyclable


© ccfb/pixabay.com

Wth a Series B €40m financing, Novadip Biosciences SA has raised investements to a total of €88m. It will use the proceeds to push two single-use cell therapies designed to accelerate healing.

© Spencerbdavies/pixabay.com

Three small-scale studies hinted at new COVID-19 vaccination boosters not significantly enhancing the immune response to Omicron variant.

Picture: Aurobac

Aurobac Therapeutics has appointed Florence Séjourné as CEO. The French company is a joint venture, founded by Boehringer Ingelheim, Evotec and bioMérieux and focuses on combating antimicrobial resistance (AMR).

Biotech cluster Vienna

Takeda, Boehringer Ingelheim and Novartis do it repeatedly. Global players make ­major investments in their Austrian facilities. Not only multinationals but start-ups and scale-ups such as ­Apeiron Biologics and ViraTherapeutics benefit from a comprehensive ecosystem – from basic research to production and distribution. The business location agency ABA is the first point of contact for setting up operations in Austria.

Adv_11_22_Eppendorf.png

Eppendorf Tubes® BioBased reduce the product-specific carbon footprint and ­support environmental friendly lab workflow.

Memo Therapeutics used its huMemoMAB platform to develop antibodies to treat cancers and infections. © Memo Therapeutics AG

Antibody developer Memo Therapeutics AG has snaged a R&D partnership with Ono Pharmaceutical Co. Ltd in the immuno-oncology field.

The L130 Laboratory Refrigerator is used worldwide to store temperature-sensitive biologicals. Picture: © B Medical Systems

Keeping biologicals at low temperatures is an established and effective way of maintaining their potency. This is critical for many types of medicines, vaccines, reagents, and biological samples, which is the reason why laboratories, hospitals, clinics, pharmacies, and more employ medical-grade refrigerators to protect their samples from ambient conditions.